VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Browse by Series:

FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More

Gina Columbus
Published: Friday, Dec 23, 2016



Gina Columbus reports on an FDA approval and a priority review in ovarian cancer, 2 CHMP recommendations in non–small cell lung cancer, disappointing results in a prostate cancer trial, a co-branding partnership between 2 institutions, and the official demise of the Part B Payment Model.
Slider Left
Slider Right


Gina Columbus reports on an FDA approval and a priority review in ovarian cancer, 2 CHMP recommendations in non–small cell lung cancer, disappointing results in a prostate cancer trial, a co-branding partnership between 2 institutions, and the official demise of the Part B Payment Model.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x